MS4A1 and follicular lymphoma: However, we suggest that a check for CD20 antigen positivity nevertheless be performed to adapt subsequent therapies for patients with relapsed or refractory follicular lymphoma, especially when immunotherapy against tumor target CD20 is targeted.